TVTX logo

Travere Therapeutics Inc. (TVTX)

$51.10

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TVTX

Market cap

$4.91B

EPS

-1.28

P/E ratio

--

Price to sales

8.31

Dividend yield

--

Beta

1.120437

Price on TVTX

Previous close

$49.70

Today's open

$49.38

Day's range

$48.25 - $51.18

52 week range

$22.59 - $68.73

Profile about TVTX

CEO

Eric Dube

Employees

497

Headquarters

San Diego, CA

Exchange

NASDAQ Global Market

Shares outstanding

95992155

Issue type

Common Stock

TVTX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on TVTX

Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy

Travere Therapeutics has achieved two significant FDA approvals for FILSPARI, driving notable revenue growth. TVTX shares have nearly tripled since the initial 'Buy' rating in August 2025, reflecting strong momentum. With two FDA-approved revenue streams, TVTX now faces questions about sustaining its exceptional upward trajectory.

news source

Seeking Alpha • Nov 16, 2026

news preview

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on November 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 65,520 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted a.

news source

Business Wire • Nov 12, 2026

news preview

Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened

Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug, Filspari.

news source

Investors Business Daily • Nov 3, 2026

news preview

Travere Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:Guggenheim Global Healthcare ConferencePresenting on Tuesday, November 10, 2026, at 8:00 a.m. ETStifel 2026 Healthcare ConferencePresenting on Wednesday, November 11, 2026, at 3:20 p.m. ETUBS Global Biopharma ConferencePresenting on Monday, November 16, 2026, at 11:20 a.m. GMTJefferies London Healthcare ConferencePresenting.

news source

Business Wire • Nov 3, 2026

news preview

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

Travere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney-disease and rare-disease pipeline.

news source

MarketBeat • Nov 3, 2026

news preview

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Travere Therapeutics Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “We remain early in reaching the more than 100,000 a.

news source

Business Wire • Nov 2, 2026

news preview

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to earnings of $0.28 per share a year ago.

news source

Zacks Investment Research • Nov 2, 2026

news preview

Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

news source

Zacks Investment Research • Nov 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Travere Therapeutics Inc.

Open an M1 investment account to buy and sell Travere Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TVTX on M1